A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-14010 (A) vs EU-Herceptin (B) and US-Herceptin (C).

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2016
This article has no abstract
Epistemonikos ID: fdd4fee52c2235422240c49e01797aa9900ee600
First added on: Feb 07, 2025